COVID-19

Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock

BOULDER, CO / ACCESSWIRE / August 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing…

4 months ago

IMUNON to Host R&D Day on September 18th

R&D Discussion in New York City to Review IL-12’s Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders,…

4 months ago

Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial

Trial to study Major Depressive Disorder using Optimi's GMP natural psilocybin capsules in conjunction with therapyVancouver, British Columbia--(Newsfile Corp. -…

4 months ago

NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company…

4 months ago

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms

Figure: 1 Elements of Ocean Biomedical Multi-pronged Malaria Program Testing Result Figure: 2 Dr. Jonathan Kurtis conducting research near Kisumu,…

4 months ago

Masimo SET® Pulse Oximetry: Superior Performance, Worldwide Presence, Immeasurable Impact

Masimo SET® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a…

4 months ago

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff

BOULDER, CO / ACCESSWIRE / August 26, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing…

4 months ago

MPOX is Emerging as a Global Threat – NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader…

4 months ago

Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies

NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen TOKYO, Aug. 23, 2024 (GLOBE…

4 months ago